Lonsurf’s efficacy was analyzed in a double-blind study, according to the report. Patients receiving the newly-approved drug lived an average of 7.1 months, while patients treated with a placebo lived an average of 5.3 months.
More articles on gastroenterology:
5 recent GI study findings to know
New drug shows potential in fighting C. diff: 4 notes
10 of the biggest GI/endoscopy stories in 2015
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
